---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-008352"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:04:32.608539+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocuphire Pharma appoints Nirav Jhaveri as CFO and Ash Jayagopal as Chief Scientific Officer

## Summary
- Nirav Jhaveri appointed CFO effective Feb 12, 2024; base salary $410k, equity awards: 210k options + 140k RSUs.
- Ash Jayagopal appointed Chief Scientific and Development Officer; 15+ years retinal disease experience, previously at Opus Genetics and Roche.
- Jhaveri previously CFO at Insilico Medicine and Journey Medical; over 20 years biopharma finance experience.
- Both appointments effective Feb 12, 2024, as company advances APX3330 phase 3 in diabetic retinopathy.
- Jhaveri eligible for discretionary annual cash bonus up to 45% of base salary; severance includes 0.75x salary plus prorated bonus.

## SEC filing metadata
- accession: 0001140361-24-008352
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036124008352/0001140361-24-008352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036124008352/ef20021883_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-008352
- JSON: https://secwatch.observer/filing/0001140361-24-008352.json
- Plain text: https://secwatch.observer/filing/0001140361-24-008352.txt

## Key facts
- Executive change
  Nirav Jhaveri was appointed as Chief Financial Officer at Opus Genetics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On February 14, 2024, Ocuphire Pharma, Inc., (the “Company”) announced the appointment of Nirav Jhaveri as the Company’s Chief Financial Officer (“CFO”), effective February 12, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036124008352/0001140361-24-008352-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.